Bio: 

As a scientist of basic research, he discovered key biologic features of endothelial progenitors and successfully applied these results into the clinical field. For example, he developed the MAGIC-CELL therapy, which is the world’s only cytokine-based autologous stem cell therapy, and applied it to patients with myocardial infarction (Lancet 2004, Circulation 2006) and proved to be an efficacious and safe novel therapy. Based on these original findings of stem cell and vascular biology, he founded a bio-venture company, Kim Cell & Gene in 2020 and is leading 40 members in his research laboratory to develop innovative biologic therapeutics. As a clinical scientist of translational research, he realized the innovative basic results into clinic by running a series of large randomized clinical landmark trials as a PI, such as, MAGIC-CELL(Lancet), EXCELLENT(Circulation), COREA-TAXUS(Lancet), HOST-ASSURE(JACC), HOST-REDUCE-ACS(Lancet), HOST-POLYTECH-ACS(Circulation), HOST-EXAM(Lancet), HOST-IDEA(Circulation), HOST-EXAM-EX(Circulation), HOST-BR RCT(Lancet). He is the representative interventional cardiologist in Korea and contributed to the establishment or revision of global guidelines to manage the patients of cardiovascular diseases. The impact or quality of his work is well reflected by the data: total citation number is over 46,355 and H index is 112 with 194 papers having impact factor over 10.